Everything below concerns GW501516. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
== Mechanism of action == GLP-1 poly-agonist peptides work by activating two hormone receptors rather than one. The two receptors targeted are both triggered naturally after eating, but they act on different parts of the body and play complementary roles in regulating blood sugar, appetite, and fat metabolism. In the pancreas, both receptors stimulate insulin release in response to elevated blood glucose, but through slightly different cellular pathways. Activating both at once produces a stronger insulin response than either receptor alone. The two receptors also balance each other in their effects on glucagon; GIP raises glucagon when blood sugar is too low, while GLP-1 suppresses glucagon when blood sugar is too high. In fat tissue, GIP promotes the removal of triglycerides from the bloodstream, while GLP-1 encourages fat breakdown through signals sent via the central nervous system. Both hormones also reduce fat build up in the liver and lower insulin resistance.
The relevant timescale is, to some degree, arbitrarily defined: 1000 seconds is sometimes employed, as this is regarded as the lower limit for the amount of time required for chemical or chromatographic separation of enantiomers in a practical sense. Molecules that are chiral at room temperature due to restricted rotation about a single bond (barrier to rotation ≥ ca. 23 kcal/mol) are said to exhibit atropisomerism. A chiral compound can contain no improper axis of rotation (Sn), which includes planes of symmetry and inversion center. Chiral molecules are always dissymmetric (lacking Sn) but not always asymmetric (lacking all symmetry elements except the trivial identity). Asymmetric molecules are always chiral. The following table shows some examples of chiral and achiral molecules, with the Schoenflies notation of the point group of the molecule. In the achiral molecules, X and Y (with no subscript) represent achiral groups, whereas XR and XS or YR and YS represent enantiomers. Note that there is no meaning to the orientation of an S2 axis, which is just an inversion. Any orientation will do, so long as it passes through the center of inversion. Also note that higher symmetries of chiral and achiral molecules also exist, and symmetries that do not include those in the table, such as the chiral C3 or the achiral S4.
==== MeSH D13.444.308 – DNA ==== MeSH D13.444.308.135 – DNA adducts MeSH D13.444.308.142 – DNA, a-form MeSH D13.444.308.148 – DNA, algal MeSH D13.444.308.150 – DNA, antisense MeSH D13.444.308.150.640 – oligodeoxyribonucleotides, antisense MeSH D13.444.308.180 – DNA, archaeal MeSH D13.444.308.212 – DNA, bacterial MeSH D13.444.308.227 – DNA, c-form MeSH D13.444.308.243 – DNA, catalytic MeSH D13.444.308.283 – DNA, circular MeSH D13.444.308.283.084 – DNA, catenated MeSH D13.444.308.283.170 – DNA, chloroplast MeSH D13.444.308.283.225 – DNA, mitochondrial MeSH D13.444.308.283.225.200 – DNA, kinetoplast MeSH D13.444.308.283.250 – DNA, superhelical MeSH D13.444.308.291 – DNA, concatenated MeSH D13.444.308.295 – DNA, cruciform MeSH D13.444.308.300 – DNA, fungal MeSH D13.444.308.315 – DNA, helminth MeSH D13.444.308.324 – DNA, intergenic MeSH D13.444.308.324.230 – DNA, ribosomal spacer MeSH D13.444.308.425 – DNA, neoplasm MeSH D13.444.308.435 – DNA, plant MeSH D13.444.308.435.275 – DNA, chloroplast MeSH D13.444.308.442 – DNA, protozoan MeSH D13.444.308.442.200 – DNA, kinetoplast MeSH D13.444.308.460 – DNA, recombinant MeSH D13.444.308.475 – DNA, ribosomal MeSH D13.444.308.475.230 – DNA, ribosomal spacer MeSH D13.444.308.480 – DNA, satellite MeSH D13.444.308.497 – DNA, single-stranded MeSH D13.444.308.497.220 – DNA, complementary MeSH D13.444.308.520 – DNA transposable elements MeSH D13.444.308.568 – DNA, viral MeSH D13.444.308.574 – DNA, z-form MeSH D13.444.308.580 – isochores MeSH D13.444.308.760 – retroelements
Sources: en.wikipedia.org
==== Eliminated in primary ==== William Abel, U.S. Army veteran David Berry, physician Steve Dowell, U.S. Army veteran Edward Ewald, retiree Abhiram Garapati, real estate investor Valentina Gomez, financial strategist and candidate for Missouri Secretary of State in 2024 (previously ran in the 2nd district) Raymond Hamden, real estate broker Elvis Lossa, policy coordinator Vince Offer, pitchman and comedian
=== Ischemic stroke === Some preliminary research suggested that citicoline may reduce the rates of death and disability following an ischemic stroke. However, the largest citicoline clinical trial to date (a randomised, placebo-controlled, sequential trial of 2,298 patients with moderate-to-severe acute ischaemic stroke in Europe), found no benefit of administering citicoline on survival or recovery from stroke. A meta-analysis of seven trials reported no statistically significant benefit for long-term survival or recovery.
=== Cholesterol clearance === Synthetic platelets are being explored for their potential in cholesterol clearance by facilitating the targeted removal of cholesterol from the bloodstream, offering a novel approach to treating hypercholesterolemia and preventing cardiovascular diseases. Elevated low-density lipoprotein cholesterol (LDL-C) is a key contributor to coronary heart disease, largely regulated by the interaction between LDL receptors (LDLR) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Since PCSK9 reduces LDLR availability, inhibiting it can enhance LDL-C clearance. To explore this, researchers designed platelet-mimicking nanoparticles to deliver siRNA targeting Pcsk9. These nanoparticles effectively lowered Pcsk9 mRNA levels by 66% in cell studies and reduced plasma LDL-C by 28% in animal models, without significantly altering high-density lipoprotein cholesterol (HDL-C) or triglycerides (TGs). This strategy demonstrates the potential of biomimetic nanoparticles for RNA-based therapies aimed at treating high cholesterol.
Sources: en.wikipedia.org
In engineering, the elasticity of a material is quantified by the elastic modulus such as the Young's modulus, bulk modulus or shear modulus which measure the amount of stress needed to achieve a unit of strain; a higher modulus indicates that the material is harder to deform. The SI unit of this modulus is the pascal (Pa). The material's elastic limit or yield strength is the maximum stress that can arise before the onset of plastic deformation. Its SI unit is also the pascal (Pa).
Copper deficiency, or hypocupremia, is defined as insufficient copper to meet the body's needs, or as a serum copper level below the normal range. Symptoms may include fatigue, decreased red blood cells, early greying of the hair, and neurological problems presenting as numbness, tingling, muscle weakness, and ataxia. The neurodegenerative syndrome of copper deficiency has been recognized for some time in ruminant animals, in which it is commonly known as "swayback". Copper deficiency can manifest in parallel with vitamin B12 and other nutritional deficiencies.
where σmax is the maximum tensile strength at the bottom of an infinite ice plate resting on an elastic foundation. The parameter C is based on the theory of thick plates. Hence, with this idealized formulation, A is representative of the ice cover tensile strength. Although recommended values for A range from 3.5 to 10 kg/cm2 (50 to 142 psi), lower bound values are generally those that are used for safety purposes. This level of conservatism is justified because, unlike human-made materials such as steel or concrete, natural ice covers inherently contain a large amount of structural flaws (fractures, water and air pockets). Moreover, for a public road, which is relatively uncontrolled, such an approach introduces a high safety factor against breakthroughs and is therefore desirable. For industrial roads, the design may be less conservative so as to handle their functional requirements, i.e. higher A values can be used, but under the close supervision of a professional engineer.
In the Western hemisphere, tostones (also known as banann peze in Haiti, tachinos or chatinos in Cuba, and patacones in Colombia, Costa Rica, Ecuador, Honduras, Panama, Peru and Venezuela) are twice-fried plantain fritters, often served as a side dish, appetizer or snack. Plantains are sliced in 4 cm (2 in) long pieces and fried in oil. The segments are then removed and individually smashed down to about half their original height. Finally, the pieces are fried again and then seasoned, often with salt. In some countries, such as Cuba, Puerto Rico and the Dominican Republic, the tostones are dipped in Creole sauce from chicken, pork, beef, or shrimp before eating. In Haiti, bannann peze is commonly served with pikliz, a slaw-like condiment made with cabbage, onions, carrots and scotch bonnet peppers. In Nicaragua, tostones are typically served with fried cheese (Tostones con queso) and sometimes with refried beans. While the name tostones is used to describe this food when prepared at home, in some South American countries the word also describes plantain chips, which are typically purchased from a store. In western Venezuela, much of Colombia and the Peruvian Amazon, patacones are a frequently seen variation of tostones. Plantains are sliced in long pieces and fried in oil, then used to make sandwiches with pork, beef, chicken, vegetables and ketchup. They can be made with unripe patacon verde or ripe patacon amarillo plantains.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.